Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 2/20 | 1.00 |
| ▸ | SLC5A2 | P31639 | 2/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 2/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 0.84 |
| ▸ | ACHE | P22303 | 2/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.84 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.84 |
| ▸ | BCHE | P06276 | 1/20 | 0.84 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 1/20 | 0.65 |
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sophoraflavanone G SCHEMBL17626648 | 1.00 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL10307524 | 1.00 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL29929533 | 1.00 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL29776828 | 1.00 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL29929166 | 1.00 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL904617 | 1.00 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL15090973 | 1.00 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| SCHEMBL10307527 | 0.93 | BACE1 (0.87) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| SCHEMBL29624625 | 0.92 | BACE1 (0.85) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Kurarinone SCHEMBL904627 | 0.92 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118787633-B | Application of sophoraflavanone G in kuh-seng extract in preparation of products for preventing and treating pathogenic bacteria of dairy cows | 山东方舟生物科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118787633-A | Application of sophoraflavanone G in kuh-seng extract in preparation of products for preventing and treating pathogenic bacteria of dairy cows | 山东方舟生物科技有限公司 | 2024-10-18 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-117462537-A | New application of sophoraflavanone G | 中央民族大学 | 2024-01-30 | — | — | CN | claimed |
| EP-4216920-A1 | ORAL CARE COMPOSITIONS COMPRISING PRENYLATED FLAVONOIDS | The Procter & Gamble Company (US) | 2023-08-02 | — | — | EP | claimed |
| CN-111983058-B | Screening method of traditional Chinese medicine anti-nonalcoholic fatty liver active substances | 云南中医药大学 | 2023-06-23 | — | — | CN | claimed |
| CN-116234560-A | Oral care compositions comprising prenylated flavonoids | 宝洁公司 | 2023-06-06 | — | — | CN | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-106309427-A | Application of Sophoraflavanone G in preparation of antidepressants and pharmaceutical composition | 宁夏医科大学 | 2017-01-11 | — | — | CN | claimed |
| CN-106265628-A | Sophoraflavanone G kills the application in Fish ectoparasite ciliate medicine in preparation | 暨南大学 | 2017-01-04 | — | — | CN | claimed |
| CN-104961717-B | The enrichment method of a kind of Sophoraflavanone G and application | 黑龙江中医药大学 | 2016-11-30 | — | — | CN | claimed |
| CN-105832718-A | Application of sophoraflavanone G in preparation of medicine for preventing and treating diabetic mellitus | 宁夏医科大学 | 2016-08-10 | — | — | CN | claimed |
| US-20160096815-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | KINKI UNIVERSITY (JP) | 2016-04-07 | — | — | US | claimed |
| CN-104961717-A | Enrichment method and application of Sophoraflavanone G | UNIV HEILONGJIANG CHINESE MEDICINE | 2015-10-07 | — | — | CN | claimed |
| US-8968755-B2 | Topical base and active agent-containing compositions, and methods for improving and treating skin | SCHLESSINGER JOEL (US) | 2015-03-03 | — | — | US | claimed |
| US-20130177618-A1 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN | SCHLESSINGER JOEL (US) | 2013-07-11 | — | — | US | claimed |
| WO-2005095375-A1 | EXTRACT OF SOPHORA FLAVESCENS FLAVONOIDS AND USES THEREOF | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2005-10-13 | — | — | WO | claimed |
| US-20050226943-A1 | Extract of sophora flavescens flavonoids and uses thereof | HUTCHISON MEDIPHARMA ENTERPRISES, LTD. (CN) | 2005-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096815-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1G, CACNA1H, CACNA1I | BACE1 638/4885SLC5A1 359/4885SLC5A2 1081/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | BACE1 465/4885SLC5A1 1563/4885SLC5A2 1228/4885 |
| US-20050226943-A1 | Extract of sophora flavescens flavonoids and uses thereof | IL1A, IL1B, TNF | BACE1 346/4885SLC5A1 2393/4885SLC5A2 3853/4885 |
| US-20130177618-A1 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN | FANCI, FANCF, FANCD2 | BACE1 4302/4885SLC5A1 3057/4885SLC5A2 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.